SNA
60
2
RSG
67
2
IRM
71
-2
PPL
67
-2
SBUX
36
4
KSS
47
-4
KR
59
10
HAL
50
4
TJX
58
-3
CHRW
56
2
FE
53
-2
AIG
66
4
LRCX
55
-6
FRT
53
3
CMG
70
-2
HST
39
-5
HRB
85
-2
WM
80
-4
BK
74
3
ZION
55
2
SNA
60
2
RSG
67
2
IRM
71
-2
PPL
67
-2
SBUX
36
4
KSS
47
-4
KR
59
10
HAL
50
4
TJX
58
-3
CHRW
56
2
FE
53
-2
AIG
66
4
LRCX
55
-6
FRT
53
3
CMG
70
-2
HST
39
-5
HRB
85
-2
WM
80
-4
BK
74
3
ZION
55
2
Financhill
Back

Aquestive Therapeutics 10K Form

Buy
51

AQST
Aquestive Therapeutics

Last Price:
3.10
Seasonality Move:
9.86%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive AQST News And Ratings

See the #1 stock for the next 7 days that we like better than AQST

AQST Financial Statistics

Sales & Book Value

Annual Sales: $50.58M
Cash Flow: $-10.41M
Price / Cash Flow: 0
Annual Sales: $-0.40
Price / Book: 0

Profitability

EPS (TTM): -0.43410
Net Income (TTM): $-28.77M
Gross Margin: $29.75M
Return on Equity: 0%
Return on Assets: -39.44%

Aquestive Therapeutics Earnings Forecast

Key Aquestive Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 8 years for AQST is 58.82%.
  • The Selling, General & Administrative Expenses for AQST have been equal to 62.77% of Gross Profit Margin.
  • The Research & Development expenses have been 25.91% of Revenue.
  • The Interest Expense is -94.82% of Operating Income.
  • The Net Earning history of AQST is -15.56% of Total Revenues.
  • Per Share Earnings over the last 8 years have been positive in 4 years.

Aquestive Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: AQST
CUSIP: 03843E
Website: aquestive.com

Debt

Debt-to-Equity Ratio: -0.79
Current Ratio: 6.28
Quick Ratio: 5.73

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

AQST Technical Analysis vs Fundamental Analysis

Buy
51
Aquestive Therapeutics (AQST) is a Buy

Is Aquestive Therapeutics a Buy or a Sell?